Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (10044)	1/16/2004 9:38:57 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Zeta, Actually VX-497 is an IMPDH inhibitor, not a protease inhibitor. There's some interesting pre-clinical discussion of combos with it and IFN and ribi at aac.asm.org I think the VRTX protease drug for HCV is about to hit the clinic. If you are interested in cancer drugs, then MSHL's phenoxodiol might be of interest. This is a souped-up genestein (from soybeans) that seems to be quite unique in terms of its effects on tumor cells. Here's a brief outline: marshalledwardsinc.com Here's a presentation that Rick found that hopefully is still available. It was around the time of their IPO, so they were limited in what they could say (actually they probably said a lot more than they should have): videonewswire.com NVGN is the safer (but less leveraged) way to play this, as they own 90% of MSHL. Peter